Actor portrayal.

NOW APPROVED FOR THE TREATMENT OF ADULTS AND ADOLESCENTS (AGED ≥12) WITH ATOPIC DERMATITIS

Itch relief like that

Relieves itch fast,
with skin healing that lasts1,2

A novel, IL-31RA–targeted biologic that delivers itch relief as soon as 48 hours,* and helps block the urge to scratch, so patients can experience skin healing that lasts1-3

SEE EFFICACY DATA 

PP-NRS response defined as a ≥4-point improvement from baseline. Data from Phase 3 clinical study (ARCADIA 1) post hoc descriptive analysis of daily PP-NRS improvement; consistent results seen in ARCADIA 2. Significant improvement was achieved at 48 hours (9% with NEMLUVIO + TCS/TCI vs 3% with placebo + TCS/TCI, P≤0.001).1,3

NEMLUVIO Unique Mechanism of Action3,4

NEMLUVIO® is the first and only neuroimmune-targeted treatment to directly block IL-31RA—blocking the signaling that drives itch, inflammation, skin barrier dysfunction, and fibrosis3,4

SEE HOW IT WORKS 

Lasting Skin Healing2

At Week 16, 44% of patients achieved significant clearance (EASI-75) vs 29% with placebo† and 36% of patients taking NEMLUVIO + TCS/TCI achieved clear (IGA 0) or almost clear (IGA 1) skin vs 25% with placebo3†

Nearly 8 out of 10 patients achieved significant clearance with over a year of treatment2‡

DISCOVER THE DIFFERENCE 

Fast Itch Relief1

Significant relief was achieved as soon as 48 hours.* Consistent results were seen in ARCADIA 1 and ARCADIA 21

VIEW THE RESULTS 

Favorable Safety Profile3

NEMLUVIO was well tolerated, has no boxed warning, and requires no preliminary lab evaluations or ongoing lab monitoring3

REVIEW SAFETY PROFILE 

Q4W Dosing From the Start3

NEMLUVIO offers the convenience of less frequent dosing for patients with AD when compared to dupilumab3,5

LEARN MORE 
GPS (Galderma Patient Services) for NEMLUVIO™ logo.

Your real-time navigation partner to help patients start and stay on NEMLUVIO

GPS (Galderma Patient Services) for NEMLUVIO™ offers:

  • Access to assistance programs and adherence support
  • Nursing support for injection training and product education

For any questions or to learn how to enroll in GPS for NEMLUVIO, please call 1-855-NEMLUVIO, 8:00 AM - 8:00 PM ET, Monday‑Friday

EXPLORE GPS FOR NEMLUVIO 

IMPORTANT SAFETY INFORMATION

INDICATIONS: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:

  • the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
  • the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are:

  • Atopic Dermatitis: headache (including migraine), arthralgia, urticaria, and myalgia. 
  • Prurigo Nodularis: headache, dermatitis atopic, eczema, and eczema nummular. 

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug- associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO have not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis or pediatric patients younger than 18 years of age for the treatment of prurigo nodularis.

Please see full Prescribing Information, including Patient Information.